Model-Informed Drug Development for Malaria Therapeutics
Malaria is a critical public health problem resulting in substantial morbidity and mortality, particularly in developing countries. Owing to the development of resistance toward current therapies, novel approaches to accelerate the development efforts of new malaria therapeutics are urgently needed. There have been significant advancements in the development of in vitro and in vivo experiments that generate data used to inform decisions about the potential merit of new compounds. A comprehensive disease-drug model capable of integrating discrete data from different preclinical and clinical components would be a valuable tool across all stages of drug development. This could have an enormous impact on the otherwise slow and resource-intensive process of traditional clinical drug development.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:58 |
|---|---|
| Enthalten in: |
Annual review of pharmacology and toxicology - 58(2018) vom: 06. Jan., Seite 567-582 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Andrews, Kayla Ann [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antimalarials |
|---|
| Anmerkungen: |
Date Completed 21.06.2019 Date Revised 14.05.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1146/annurev-pharmtox-010715-103429 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM276616480 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM276616480 | ||
| 003 | DE-627 | ||
| 005 | 20231225012424.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1146/annurev-pharmtox-010715-103429 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0922.xml |
| 035 | |a (DE-627)NLM276616480 | ||
| 035 | |a (NLM)28992431 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Andrews, Kayla Ann |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Model-Informed Drug Development for Malaria Therapeutics |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.06.2019 | ||
| 500 | |a Date Revised 14.05.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Malaria is a critical public health problem resulting in substantial morbidity and mortality, particularly in developing countries. Owing to the development of resistance toward current therapies, novel approaches to accelerate the development efforts of new malaria therapeutics are urgently needed. There have been significant advancements in the development of in vitro and in vivo experiments that generate data used to inform decisions about the potential merit of new compounds. A comprehensive disease-drug model capable of integrating discrete data from different preclinical and clinical components would be a valuable tool across all stages of drug development. This could have an enormous impact on the otherwise slow and resource-intensive process of traditional clinical drug development | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a controlled human malaria infection | |
| 650 | 4 | |a disease-drug model | |
| 650 | 4 | |a malaria | |
| 650 | 4 | |a model-informed drug development | |
| 650 | 4 | |a pharmacodynamics | |
| 650 | 4 | |a pharmacokinetics | |
| 650 | 7 | |a Antimalarials |2 NLM | |
| 700 | 1 | |a Wesche, David |e verfasserin |4 aut | |
| 700 | 1 | |a McCarthy, James |e verfasserin |4 aut | |
| 700 | 1 | |a Möhrle, Jörg J |e verfasserin |4 aut | |
| 700 | 1 | |a Tarning, Joel |e verfasserin |4 aut | |
| 700 | 1 | |a Phillips, Luann |e verfasserin |4 aut | |
| 700 | 1 | |a Kern, Steven |e verfasserin |4 aut | |
| 700 | 1 | |a Grasela, Thaddeus |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annual review of pharmacology and toxicology |d 1993 |g 58(2018) vom: 06. Jan., Seite 567-582 |w (DE-627)NLM000078379 |x 1545-4304 |7 nnns |
| 773 | 1 | 8 | |g volume:58 |g year:2018 |g day:06 |g month:01 |g pages:567-582 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1146/annurev-pharmtox-010715-103429 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 58 |j 2018 |b 06 |c 01 |h 567-582 | ||